TPMP Rule Stalled: Build to the Standard Anyway

FDA found nicotine label variance of 35% to 52% in ENDS products during its surveillance testing. That number appeared in the preamble to the proposed Tobacco Product Manufacturing Practices (TPMP) rule, published March 10, 2023. It was the clearest signal the agency had ever sent about where quality expectations were heading for tobacco product manufacturing.

Then, in January 2025, the TPMP rule moved to "Long-Term Action" on the Unified Regulatory Agenda. In regulatory terms, that is one step above indefinite postponement. The rule proposing 21 CFR Part 1120, which would have imposed design controls, production process controls, and master manufacturing records on the tobacco product industry, is effectively stalled.

Some manufacturers read that as a reprieve. They should not. The first authorized nicotine pouch PMTAs tell a different story about what FDA actually expects from manufacturers, regardless of whether the TPMP rule ever reaches final form.

What the TPMP Rule Proposed

The proposed rule, published at 88 FR 15058 under Docket FDA-2023-04591 (RIN 0910-AH91), laid out a comprehensive quality system framework for tobacco product manufacturing. The key subparts translate directly to operational requirements:

Subpart D: Design Controls. Manufacturers would need documented design and development procedures for new and modified tobacco products. This includes design inputs, design verification and validation, design reviews, and design transfer to production. For nicotine pouch manufacturers, this means formulation development would require the same rigor that pharmaceutical and medical device companies apply to their design processes.

Subpart E: Production and Process Controls. Every production process affecting product quality would need documented procedures, validated processes, and monitoring controls. This covers everything from ingredient receiving through finished product release, including in-process testing, environmental controls, and equipment qualification.

Subpart G: Master Manufacturing Record. Each tobacco product would require a master manufacturing record containing the complete formulation, manufacturing instructions, specifications, and quality control procedures. This is the foundation document that makes production reproducible and auditable.

Subpart I: Small Manufacturer Delay. The proposed rule included a delayed compliance timeline for small manufacturers, acknowledging the cost burden on smaller operations.

The estimated compliance cost: $27.0 million per year across the regulated industry. That figure, from FDA's own regulatory impact analysis, accounts for the documentation, testing, and quality system infrastructure the rule would require.

Why "Long-Term Action" Does Not Mean "Never"

The Unified Regulatory Agenda classifies rules in four categories: Prerule, Proposed Rule, Final Rule, and Long-Term Action. Long-Term Action means the agency does not expect to take action on the rule within the next 12 months. It does not mean the rule is withdrawn. It does not mean the agency has abandoned its quality expectations.

Three factors suggest the TPMP standard is alive in practice even if the formal rule is stalled.

First, the authorized PMTAs demonstrate the standard implicitly. ZYN received marketing authorization in January 2025 for 20 products. Altria's on! PLUS received authorization in December 2025 for six products. Both authorizations came from applicants with pharmaceutical-grade quality systems already in place. Philip Morris International and Altria did not build those systems because a TPMP rule required it. They built them because FDA's PMTA review process effectively requires the same level of documentation, process control, and traceability that the TPMP rule would formalize.

Second, FDA's surveillance data justified the rule in the first place. The 35% to 52% nicotine label variance finding did not disappear when the rule moved to Long-Term Action. FDA continues to conduct post-market surveillance. Products with inconsistent nicotine delivery are products that fail the "appropriate for the protection of public health" standard under Section 910(c)(2) of the FD&C Act. Consistency problems will surface in PMTA reviews whether or not the TPMP rule is final.

Third, deficiency letters reference quality system gaps. When FDA issues deficiency letters during PMTA review, the requests for additional information frequently target manufacturing consistency, process validation, and batch-to-batch reproducibility. These are TPMP concepts applied through a different mechanism. A manufacturer that receives a deficiency letter about production consistency is, in effect, being asked to demonstrate TPMP-equivalent controls.

The Authorized Pouch PMTAs Set the Implicit Benchmark

The ZYN and on! PLUS authorizations are not just regulatory milestones. They are public benchmarks for what a successful PMTA manufacturing package looks like.

Both applicants demonstrated comprehensive quality systems that align with TPMP's proposed requirements. Their applications documented design controls for product development, validated production processes, batch-level traceability, and in-process quality testing. They provided evidence of manufacturing consistency through analytical data showing batch-to-batch nicotine delivery uniformity.

For manufacturers preparing their own PMTA applications, these authorizations set the competitive standard. FDA reviewers who have seen applications with pharmaceutical-grade quality documentation will evaluate subsequent applications against that baseline. A manufacturer that submits a PMTA with informal quality practices and undocumented process controls is competing against applicants who have already demonstrated what "good" looks like.

The practical question is not whether TPMP will become law. The practical question is whether your manufacturing documentation will survive the same scrutiny that ZYN and on! PLUS applications received.

The Cost of Retrofitting After a Deficiency Letter

Building TPMP-equivalent controls proactively costs a fraction of retrofitting them under regulatory pressure. The math works in three dimensions.

Time. A deficiency letter from FDA typically carries a response deadline of 90 to 180 days. Building a quality system from scratch in that window, while maintaining production, is an emergency exercise that disrupts operations and diverts resources from revenue-generating activities. Manufacturers who build these systems before submission have the luxury of phased implementation over months or years.

Money. FDA's $27.0 million per year industry-wide compliance estimate is the cost of building systems correctly the first time. Retrofitting under pressure costs more because it requires expedited consulting, accelerated validation studies, and production slowdowns during implementation. Emergency quality system implementations also carry higher error rates, which can generate additional deficiency findings.

Risk. A PMTA application that receives a deficiency letter about manufacturing controls is an application that may never recover. Each round of deficiency letters extends the review timeline. Based on ZYN's nearly five-year review cycle from March 2020 to January 2025, even a well-prepared application faces multi-year review periods. Adding deficiency letter cycles to that baseline pushes authorization further out, during which time the product remains unauthorized and competitors with authorizations gain market share.

What TPMP-Equivalent Controls Look Like for Ingredient Sourcing

The TPMP rule's proposed requirements cascade through the supply chain. Manufacturers cannot demonstrate production process controls if their incoming ingredient specifications are inconsistent. They cannot maintain a master manufacturing record if ingredient documentation changes format or content from lot to lot.

For nicotine, the primary active ingredient in pouch and e-liquid formulations, TPMP-equivalent sourcing means the following:

Consistent grade specifications. USP/EP grade nicotine provides the pharmacopoeial reference standard that TPMP's design control requirements anticipate. Each lot meets the same documented specification, which means the manufacturer's master manufacturing record remains valid across production batches without requiring re-qualification for each incoming lot.

Batch-level Certificates of Analysis. Production process controls under Subpart E require that incoming materials be verified against specifications before use. A CoA that includes assay percentage, full impurity profile, and grade certification for each specific batch is the documentation that satisfies incoming material verification. A generic CoA covering "typical" values is not sufficient for a quality system that must demonstrate batch-level traceability.

Salt form documentation for formulation consistency. Manufacturers using nicotine salts in pouch formulations need salt-form-specific documentation that connects the ingredient specification to the finished product's nicotine delivery profile. The TPMP design control requirements would make this connection explicit: the ingredient specification is a design input, and the finished product nicotine delivery is a design output that must be verified.

Stable supply chain traceability. Subpart G's master manufacturing record requirements include ingredient sourcing documentation. A supplier that provides full seed-to-shipment traceability produces the documentation that populates this section of the record. A supplier that provides only a CoA leaves the manufacturer to fill that gap independently.

Audit-ready manufacturing partner documentation. The TPMP rule's production and process control requirements extend to contract manufacturers and, by implication, to ingredient suppliers whose processes affect the finished product. GMP, ISO 9001, and HACCP certifications at the supplier's manufacturing partner facility provide the documented evidence that the ingredient supply chain meets the quality system expectations the TPMP rule would formalize.

Building Now vs. Waiting: A Decision Framework

Manufacturers evaluating whether to invest in TPMP-equivalent controls before the rule is finalized should consider three scenarios.

Scenario 1: The TPMP rule reaches final form within 2-3 years. Manufacturers who built proactively are already compliant. Manufacturers who waited face the estimated $27.0 million per year industry compliance cost under deadline pressure, with competitors who prepared early gaining first-mover advantage in authorized product filings.

Scenario 2: The TPMP rule remains stalled indefinitely. Manufacturers who built proactively still benefit. Their PMTA applications contain stronger manufacturing documentation. Their production is more consistent, reducing waste and quality failures. Their quality systems meet the implicit benchmark set by the ZYN and on! PLUS authorizations. The investment was not wasted because the standard is being applied even without the rule.

Scenario 3: FDA replaces the TPMP rule with guidance or enforcement discretion. Even softer alternatives would reference the same quality system concepts. Design controls, process validation, and master manufacturing records are not TPMP inventions. They are established quality principles that FDA has applied to every other regulated product category. A guidance document would describe the same expectations in non-binding language.

In all three scenarios, the manufacturer who builds to the TPMP standard is better positioned. The only scenario where waiting is advantageous is one where FDA permanently abandons all manufacturing quality expectations for tobacco products. That scenario is not consistent with the agency's stated public health mission or its track record across other regulated industries.

The Ingredient Supplier's Role in TPMP Readiness

Nicotine ingredient suppliers occupy a specific position in the TPMP framework. The proposed rule targets manufacturers, not suppliers directly. But a manufacturer cannot demonstrate compliance with production and process controls, design controls, or master manufacturing record requirements if its primary active ingredient arrives without the documentation those controls demand.

This creates a practical filter. Manufacturers building TPMP-equivalent quality systems will select suppliers whose documentation supports that system. Suppliers who provide batch-level CoAs, traceability records, stability data, and audit-ready manufacturing partner credentials become quality system components. Suppliers who provide only a product and a price become liabilities.

The PMTA fast-track pilot cancellation reinforced this dynamic. With full 21 CFR Part 1114 review as the only pathway, documentation quality at the ingredient level is more important than it has ever been. TPMP readiness and PMTA readiness are, in practice, the same investment.

NicAlliance provides USP/EP grade nicotine with batch-level documentation, full supply chain traceability, and a certified US-based manufacturing partner whose quality credentials support TPMP-equivalent quality systems. If your quality team is evaluating ingredient suppliers against the TPMP benchmark, request a sample with full documentation and compare it against what your current supplier provides.

Frequently Asked Questions